Luvometinib
As of the edition of 20 October 2026, Luvometinib is a small molecule: in active development; acts on MAP2K1 and MAP2K2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 13, 0 stopped early
- Disease areas
- Cancer; Inherited and neonatal; Nervous system; Blood and lymph; Lungs and airways; Ear, nose and throat
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 0 | 2 | 0 |
| Phase 2 | 9 | 0 | 9 | 0 |
| Phase 3 | 2 | 0 | 2 | 0 |
| All trials | 13 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Fosun Pharmaceutical Industrial | Lead sponsor of trials | 2021 to now |